Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
Year: 2011
Type: article
Source: Annals of the Rheumatic Diseases
Institutions: Universitätsklinikum Tübingen, University Children's Hospital Tübingen, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, University College London, Bicêtre Hospital, Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Université Paris Descartes, Universitätsklinikum Gießen und Marburg, Istituto Giannina Gaslini, University of Genoa, Istanbul University, University of Wisconsin–Madison, University of California, San Francisco, University of California San Francisco Medical Center, Universidad de Oviedo, Hospital Universitario Central de Asturias, Novartis (United States), Novartis (Switzerland)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funders: Novartis, Novartis Pharma
OpenAlex ID: W2125374122
